SCHEMBL369192

SCHEMBL369192

COc1ccc(Cn2cc(I)c(C(C)=O)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.44
NPC1 O15118 4/20 0.43
KMT2A Q03164 3/20 0.43
RAB9A P51151 3/20 0.43
CACNA1G O43497 3/20 0.43
CACNA1H O95180 3/20 0.43
CACNA1I Q9P0X4 3/20 0.43
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HDAC1 Q13547 1/20 0.42
CMA1 P23946 1/20 0.42
SNCA P37840 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
GAA P10253 1/20 0.40
CYP19A1 P11511 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370291 0.89 KMT2A (0.46) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL369627 0.88 CACNA1G (0.45) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL899018 0.85 AADAT (0.45) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL365784 0.85 CACNA1G (0.43) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL370013 0.85 MAPT (0.46) KMT2AMEN1L3MBTL1SMN1; SMN2GAA
SCHEMBL6837473 0.83 AADAT (0.43) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL957961 0.81 NPC1 (0.52) NPC1KMT2ARAB9ACACNA1GCACNA1H
SCHEMBL370625 0.79 MEN1 (0.44) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL370819 0.78 CMA1 (0.44) AADATNPC1KMT2ARAB9ACACNA1G
SCHEMBL370498 0.78 L3MBTL1 (0.43) AADATNPC1KMT2ARAB9ACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
US-20130210807-A1 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. MERCK SHARP & DOHME CORP. 2013-08-15 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012006760-A1 TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed
WO-2012008999-A2 TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210807-A1 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. GRM3, GRM6, GRM1 AADAT 3254/4885NPC1 3248/4885KMT2A 701/4885
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885NPC1 1787/4885KMT2A 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.